- Home
- TSAT vs LRMR Comparison
TSAT vs LRMR Comparison
Compare TSAT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSAT | LRMR |
|---|---|---|
| Founded | 1969 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.8M | 332.1M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | TSAT | LRMR |
|---|---|---|
| Price | $26.13 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 92.4K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $324,440,552.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.65 | $1.61 |
| 52 Week High | $36.85 | $6.91 |
Technical Indicators
Market Signals| Indicator | TSAT | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 46.32 |
| Support Level | $23.01 | $3.32 |
| Resistance Level | $25.87 | $3.79 |
| Average True Range (ATR) | 1.47 | 0.24 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 64.39 | 58.77 |
Price Performance
Historical ComparisonAbout TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.